Immunogenicity of Biopharmaceuticals (häftad)
Fler böcker inom
Format
Häftad (Paperback / softback)
Språk
Engelska
Antal sidor
266
Utgivningsdatum
2010-11-19
Upplaga
Softcover reprint of hardcover 1st ed. 2008
Förlag
Springer-Verlag New York Inc.
Medarbetare
Møller, Eva Horn (ed.), Weert, Marco (ed.)
Illustrationer
XII, 266 p.
Dimensioner
254 x 178 x 15 mm
Vikt
490 g
Antal komponenter
1
Komponenter
1 Paperback / softback
ISBN
9781441926081

Immunogenicity of Biopharmaceuticals

av Marco Weert, Eva Horn Mller
Häftad,  Engelska, 2010-11-19
2403
Köp
Spara som favorit
  • Skickas från oss inom 7-10 vardagar.
  • Fri frakt över 249 kr för privatkunder i Sverige.
Finns även som
Visa alla 2 format & utgåvor
A particular issue for biopharmaceuticals that has not been addressed comprehensively in any book, is the potential of an immune response to the biopharmaceutical product. That is, the human body marks the drug as a foreign body, and develops antibodies against the drug. These antibodies may be relatively harmless, but may also cross-react with the endogenous compound, causing autoimmunogenicity. Recent adverse experiences in Europe with Janssen-Orthos blockbuster product Eprex has increased the attention towards potential immunogenicity of biopharmaceuticals, above all from the regulatory agencies. This book is intended to give a broad overview of the current state-of-the-art regarding the immune response to biopharmaceuticals. The chapters range from an overview of the immune system and factors that may trigger the immune system, via detection of antibodies and clinical implications, to various case examples and the regulatory view on immunogenicity.
Visa hela texten

Passar bra ihop

  1. Immunogenicity of Biopharmaceuticals
  2. +
  3. Bad Therapy

De som köpt den här boken har ofta också köpt Bad Therapy av Abigail Shrier (inbunden).

Köp båda 2 för 2668 kr

Kundrecensioner

Har du läst boken? Sätt ditt betyg »

Innehållsförteckning

Immune Reactions Towards Biopharmaceuticals a General, Mechanistic Overview.- Clinical Aspects of Immunogenicity to Biopharmaceuticals.- Assessment of Unwanted Immunogenicity.- Models for Prediction of Immunogenicity.- Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars.- Case Study: Immunogenicity of rhEPO.- Case Study: Immunogenicity of Interferon-Beta.- Case Study: Immunogenicity of Insulin.- Case Study: Immunogenicity of Factor VIII.- Case Study: Immunogenicity of Natalizumab.- Case Study: Immunogenicity of Anti-TNF Antibodies.- Heparin-Induced Thrombocytopenia.- Presenting an Immunogenicity Risk Assessment to Regulatory Agencies.

Du kanske gillar